Stocks | | |
Canopy Growth stock (NYSE:CGC) closed down 14% on Thursday having been down by as much as 17% during the trading session following its quarterly earnings report.
The Canadian based cannabis company’s sales, earnings, and revenue disappointed investors yet again. To be fair, revenue was up b... Read the Full Story |
|
From Our PartnersLet James Altucher spell it out for you. A special plan from one of the most profitable companies in marijuana… What he’s calling “WEED-tirement” has the power to double your retirement savings. Find out why you haven’t heard about this shocking opportunity yet. | | Click here for all the details. |
|
Markets | | |
There's a reason Warren Buffett is known as the Wizard of Omaha. He has a near-prescience when it comes to picking stocks. Sure, he's seen his share of failures but understanding the market seems to come more readily to him than the average person. Therefore, his moves—and by extension Berks... Read the Full Story |
|
Stocks | | |
Shares of Nvidia (NASDAQ: NVDA) were trading down 4% at one point during Friday’s session following the company’s fiscal third-quarter earnings release on Thursday evening.
The California based company is known for producing the graphics processing units and chips used in the gaming, ... Read the Full Story |
|
From Our PartnersInvestors looking for some of the stock market's fastest-growing companies have a number of outstanding choices on the Nasdaq.
What follows is a list of five stocks chosen for their potential to deliver impressive gains over the next 12 months - the 5 Top Nasdaq Stocks to Watch for the Next 12 Months. | | Free Report Here. |
|
Markets | | |
Every single day when the market opens, a battle between buyers and sellers begins and the prices of securities start moving. It can really pay off to review the basic economic concept of supply and demand before you start trading or investing. That being said, many new traders and investors strug... Read the Full Story |
|
Markets | | | In this era of algorithm-driven financial markets, stock prices can be volatile and extreme. Often a stock price overreaction (steep sell-off) can present a compelling buying opportunity. Unfortunately, this tends to materialize in the “rearview mirror” well after prices recover. A simpl... Read the Full Story |
|
From Our PartnersLet James Altucher spell it out for you. A special plan from one of the most profitable companies in marijuana… What he’s calling “WEED-tirement” has the power to double your retirement savings. Find out why you haven’t heard about this shocking opportunity yet. | | Click here for all the details. |
|
The Early Bird Stock Of The Day Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
